Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Taki who wrote (123257)	11/21/2003 1:40:08 PM
From: Taki	Respond to of 150070

HTDS .03.News earlier.Hard to Treat Diseases Incorporated - HTDS - Updates Corporate We Site Hard to Treat Diseases Incorporated - HTDS - Updates Corporate Web Site Health/Medical Writers / Business Editors DELRAY BEACH, Fla.--(BUSINESS WIRE)--HTDS-- Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) announces today that in an effort to keep HTTD shareholders abreast of all company developments, the Company updates the web site and its new web address, httddirect.com. The Company will update its web site as new developments occur and plan to unveil the packaging for holistic Tubercin(R) very soon. As mentioned in an earlier press release, testing of Tubercin(R) has begun by a US medical group. The Company will inform its shareholders of the status of all testing and will publish the results once they become available. Tubercin(R) is a remarkable substance that is derived from Mycobacterium Tuberculosis. It is purified until it is a safe, non-toxic and a non-addictive substance. Tubercin(R) is a combative substance against cancer. An Immunostimulant, Tubercin(R) increases the strength in the immune system so that is capable of destroying the cancer cells. Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin(R), a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects". Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL MEDICAL E-COMMERCE INTERNET PRODUCT SOURCE: Hard to Treat Diseases Incorporated CONTACT INFORMATION: Hard to Treat Diseases Incorporated, Delray Beach Colm King, 561/272-6900 Colm@httddirect.com * end of story *